CytoDyn Inc (OTCQB: CYDY) said it has appointed Chiral Pharma Corp to register its leronlimab treatment, Vyrologix, in the Philippines under a licensed physician’s request for a Compassionate Special Permit (CSP) to treat coronavirus (COVID-19) patients with the therapy for a fee.
The biotechnology firm said it will dedicate at least 100,000 doses of leronlimab from its inventory to Chiral Pharma for potential sales in the Philippines, adding that last night its team presented the results from various studies (primarily from US eIND patients) of leronlimab as a potential therapeutic for COVID-19 patients to several Philippine regulators, hospital executives, and physicians.
READ: CytoDyn says US FDA accepts protocol for adding open-label extension to its Phase 3 trial; research paper published
CytoDyn also said that it has appointed Chiral Pharma to register Vyrologix for potential approval from the Food and Drug Administration in the Philippines to treat patients with COVID-19.
“We are very pleased to initiate sales of Vyrologix (leronlimab) in the Philippines as soon as we have CSP approved for patients. Under the CSP program, we will also generate significant data from Philippine patients with COVID-19. We continue to look forward to unblinding the data from our Phase 2b/3 clinical trial very soon and remain optimistic given the results from many eIND patients in the USA, who were in a similar clinical condition as the patients in our CD12 trial”, CytoDyn president and chief executive Nader Pourhassan said in a statement.
Contact the author at calum@proactiveinvestors.com
Follow him on Twitter @Cal_Proac